ArticlePathologie (Heidelberg, Germany)2026
[Cervical cancer screening in Germany 2020-2022 : An analysis of the first round of screening according to the specifications of the oKFE-RL].
Article in Pathologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2020, the Organised Early Cancer Diagnosis Guideline (eKFE-RL) programme was introduced in Germany. Women up to the age of 34 years are entitled to annual cytology-based screening. Women aged 35 years and over are entitled to a combined test (cytology and HPV) every 3 years. An age-related assessment algorithm determines the procedure if there are abnormal findings.
methodA total of 222,851 data were evaluated and analysed from the first round of screening in 2020-2021 according to the oKFE-RL: the prevalence of HPV, its age distribution in general and in HPV-positive findings (n = 10,405), as well as the distribution of HPV 16, 18 and other HPV types, are shown in cervical intraepithelial neoplasia (CIN) lesions. CIN 3 lesions are depicted and compared with the baseline value for 2019.
resultsA threefold increase in CIN 3 compared with 2019 was determined. The peak age for CIN 3 is in women aged 35-39 years. The HPV-positive rate is 8.11 %.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.